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Abstract
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most
epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many
genes and few HN entities, and comprehensive studies are required.
Methodology/Principal Findings: Here, we report for the first time a microarray-based DNA methylation study of 767 genes
in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as
well as 37 samples from different cell types of the hematopoietic system. Using appropriate controls of B-, T-, or myeloid
cellular origin, we identified a total of 220 genes hypermethylated in at least one HN entity. In general, promoter
hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center
mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-
associated DNA hypermethylation. We also observed a significant correlation between the number of hypermethylated and
hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias. Most of the genes
becoming hypermethylated contained promoters with high CpG content, and a significant fraction of them are targets of
the polycomb repressor complex. Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation
and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression.
Conclusions/Significance: We have characterized the DNA methylation profile of a wide range of different HNs entities. As
well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes—DBC1,
DIO3, FZD9, HS3ST2, MOS, and MYOD1—that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies.
These might therefore play an important role in the development of different HNs.
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Introduction
Hematological neoplasms (HNs) comprise a highly heteroge-
neous group of diseases showing different genetic, transcriptional,
phenotypical and clinical features [1]. It is widely accepted that the
acquisition of genetic changes taking place at different stages of
maturation of the hematopoietic lineages plays an essential role in
the development of HNs [2,3]. These alterations include
irreversible changes in the DNA sequence, like mutations,
translocations, deletions, amplifications, etc. that result in gene
activation or inactivation. Epigenetic changes, which represent
reversible modifications that affect gene expression without
altering the DNA sequence itself, are also a hallmark of cancer
[4,5]. The best studied epigenetic change is the hypermethylation
of tumor suppressor genes which is reported to be associated with
gene inactivation [6]. DNA methylation changes have been
frequently described in various subtypes of HNs [7,8,9]. Most
epigenetic studies in HNs have focused on the analysis of few
tumor suppressor genes and several recent publications have
characterized the DNA methylome of HNs by microarray-based
approaches [10,11,12,13,14,15,16,17,18,19,20] These reports
focused only on one or few HN subtypes. Therefore, the aim of
our study was to provide a comparative overview of the DNA
methylome of a wide range of HNs, including tumors of B-cell, T-
cell and myeloid origin.
Materials and Methods
Patient samples and controls
A total of 367 samples from patients affected with HNs were
analyzed in the present study, covering 16 different entities of B-cell,
T-cell and myeloid origin. These included 9 B-cell neoplasms: diffuse
large B-cell lymphoma (DLBCL, n = 54), molecular Burkitt lympho-
ma (mBL, n = 18), intermediate lymphoma (INT, n = 16) with a gene
expression profile between mBL and non-mBL (i.e. DLBCL) [16],
follicular lymphoma (FL, n = 14), mantle cell lymphoma (MCL,
n = 10), multiple myeloma (MM, n = 14), B-cell chronic lymphocytic
leukemia (B-CLL, n = 25), mucosa-associated lymphoid tissue
(MALT) lymphoma (n = 10) and precursor B-cell acute lymphoblastic
leukemia (B-ALL, n = 42). Four T-cell neoplasia entities were
included: precursor T-cell acute lymphoblastic leukemia (T-ALL,
n = 18), sorted CD3-positive cells of T-cell prolymphocytic leukemia
(T-PLL, n = 4), anaplastic large cell lymphoma (ALCL, n = 3) and
peripheral T-cell lymphoma (PTCL, n = 5). Finally, three myeloid
leukemia subtypes were also included in the analysis: acute myeloid
leukemia (AML, n = 116), myelodysplastic syndrome/myeloprolifer-
ative syndrome (MDS/MPS, n = 13) and chronic myelogenous
leukemia (CML, n = 5). Some of the above listed entities comprise
several sub-entities based on genetic, transcriptional or morphological
analyses. However, as the goal of this study is to provide a global
overview of DNA methylation changes in HNs, these sub-entities
were not considered in detail for the present analysis. Three separate
publications published or in preparation which will rely partly on the
same dataset provide a detailed analysis of different subtypes of
mature aggressive B-cell lymphomas (i.e. DLBCL, mBL and INT)
[16], B- and T-ALL (Agirre et al., in preparation), and AML (Alvarez
et al., in preparation).
As control samples, we used eight tissues or cell types from the
hematopoietic system. These included whole peripheral blood
(WPB, n = 4), whole bone marrow (WBM, n = 4), peripheral blood
lymphocytes (PBL, n = 7), CD34-positive cells from BM (n = 4),
CD3-positive T-cells from PB (n = 5), CD19-positive B-cells from
PB (n = 5), germinal center B-cells (GCB, n = 2) as well as B-cell
lymphoblastoid cell lines (LBL, n = 6) [16].
DNA methylation profiling using universal BeadArrays
Microarray-based DNA methylation profiling was performed
on all 367 hematological neoplasms and the 37 control samples
with the GoldenGate Methylation Cancer Panel I (Illumina, Inc.).
247 samples were processed at the Illumina Headquarters (San
Diego, CA) and 157 at the Spanish National Cancer Center
(CNIO, Madrid, Spain). The panel is developed to assay 1505
CpG sites selected from 807 genes, which include oncogenes and
tumor suppressor genes, previously reported differentially meth-
ylated or differentially expressed genes, imprinted genes, genes
involved in various signaling pathways, and genes responsible for
DNA repair, cell cycle control, metastasis, differentiation and
apoptosis.
Methylation assay was performed as described previously [21].
Briefly, for each CpG site, four probes were designed: two allele-
specific oligos (ASO) and two locus-specific oligos (LSO). Each
ASO-LSO oligo pair corresponded to either the methylated or
unmethylated state of the CpG site. Bisulfite conversion of DNA
samples was done using the EZ DNA methylation kit (Zymo
Research, Orange, CA). After bisulfite treatment, the remaining
assay steps were identical to the GoldenGate genotyping assay [22]
using Illumina-supplied reagents and conditions. The array
hybridization was conducted under a temperature gradient
program, and arrays were imaged using a BeadArray Reader
(Illumina Inc.). Image processing and intensity data extraction
software were performed as described previously [23,24]. Each
methylation data point is represented by fluorescent signals from
the M (methylated) and U (unmethylated) alleles. Background
intensity computed from a set of negative controls was subtracted
from each analytical data point. The ratio of fluorescent signals
was then computed from the two alleles according to the following
formula:
Beta~
Max M,0ð Þ
Max U ,0ð ÞzMax M,0ð Þz100 ð1:1Þ
The beta value is a quantitative measure of DNA methylation
levels of specific CpGs, and ranges from 0 for completely
unmethylated to 1 for completely methylated.
The high reproducibility of the GoldenGate Methylation
Cancer Panel I (mean coefficient of determination (R2) = 0.99)
has been demonstrated previously [16].
Before analyzing the methylation data, we excluded possible
sources of biological and technical biases that could alter the
results. A known biological factor is that one copy of
chromosome X is methylated in women and therefore, to avoid
a gender-specific bias, all 84 CpGs on chromosome X were
excluded from further analyses. Additionally, as the microarray
experiments were run in two different labs using different
BeadArray versions of the GoldenGate Methylation Cancer
Panel I, we performed a differential methylation analysis to
identify possible technical biases. We identified a total of 11
CpGs differentially methylated between the laboratories/
platforms (p-value ,0.01 and difference between mean beta
values .0.2). After excluding 84 gender-specific CpGs and 11
CpGs showing interlab (i.e. interarray version) differential
methylation, a total of 1410 CpGs from 767 genes entered
further statistical analyses.
All DNA methylation data are available as Table S1, Table S2,
and Table S3). All data is MIAME compliant as detailed on the
MGED Society website http://www.mged.org/Workgroups/
MIAME/miame.html.
DNA Methylation in Lymphomas
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Hierarchical cluster analysis and differential methylation
analysis
Hierarchical clustering was performed on all 367 cases and 30
controls using the Cluster Analysis tool of the BeadStudio software
(version 3). Since PBLs contain a mixture of B and T cells, they
were not used as control samples either for B cell or for T cell
neoplasms.
Differential methylation analysis (DMA) was performed using
the BeadStudio software (version 3). Different subtypes of B-cell,
T-cell and myeloid tumors were compared with appropriate
control samples (outlined in the results section). Two criteria were
used to detect significantly differentially methylated CpGs. First, a
false discovery rate (FDR) below 0.01 (Mann-Whitney U test) and
a mean DNA methylation (Beta) values between tumors and
controls showing a difference of at least 0.3. The statistical power
of the Mann-Whitney U test was low for some comparisons due to
small sample sizes. Therefore, a second criterion was used in which
clear differential methylation was defined as a mean Beta values
between tumors and controls showing a difference of at least 0.5. A
CpG was then classified as differentially methylated if any, or both,
criteria were met.
Venn diagrams
To compare lists of genes differentially methylated in B-cell, T-
cell and myeloid tumors, Venn diagrams were performed using the
GeneVenn software developed at the University of Southern
Mississippi (http://mcbc.usm.edu/genevenn/) [25].
Correlation between DNA hypermethylation and
hypomethylation
Pearson correlation coefficients and scatter plots were used to
study the association between de novo gain and loss of gene-
associated DNA methylation in different subtypes of hematological
tumors (SPSS, version 15.0).
Association between DNA hypomethylation and gene
expression in T-PLL
Gene expression values of 66 tags from 39 hypomethylated
genes in CD3-positive cells from five T-PLL cases (including two
T-PLLs studied herein) were compared with eight normal CD3-
positive samples from peripheral blood using data generated with
the Affymetrix U133A array [26] (raw expression data has been
deposited in a MIAME compliant format in the GEO database,
accession number GSE5788). A fold change (in log2 scale) was
calculated between the mean of gene expression data per tag in T-
PLLs and T-cell controls.
Enrichment for polycomb repressor complex 2 (PRC2)
marks and promoter classes in differentially methylated
genes
Proportions of PRC2 target genes and promoter classes in genes
differentially methylated in various HNs (only those with at least
eight differentially methylated genes were included) and all genes
analyzed with the Illumina BeadArray were compared using the
Fisher’s exact test (SPSS, version 15.0). A genome-wide mapping
of PRC2 genes in embryonic stem cells was available as
supplemental material of the study by Lee et al. [27]. To analyze
whether promoter regions of differentially methylated genes
showed different CpG compositions, we used a recently described
classification into promoters with high (HCP), intermediate (ICP)
and low (LCP) CpG content [28].
Results
DNA methylation profiling of different control samples
from the hematopoietic system
As DNA methylation patterns are tissue and cell type specific [29],
the application of proper control samples is a main issue to detect de
novo DNA methylation changes in tumor samples. To identify
suitable controls for HNs of B-cell, T-cell and myeloid origin, we
generated DNA methylation profiles of eight tissues or cell types from
the hematopoietic system. As mentioned in the materials section,
these included 37 samples from eight tissues or cell types of the
hematopoietic system: WPB (n = 4), WBM (n = 4), PBL (n = 7),
CD34-positive cells (n = 4), CD3-positive T-cells (n = 5), CD19-
positive B-cells (n = 5), GCB cells, (n = 2) and LBL cell lines (n = 6).
A hierarchical cluster analysis of 1410 CpGs (from 767 genes)
entering the statistical analyses showed that different control samples
display differential DNA methylation patterns. We then compared
the mean per CpG in each group with the mean per CpG in each of
the other groups and identified genes showing differential methyl-
ation (defined as a difference of mean Beta values above 0.5)
(Figure 1). No significant differences were detected between whole
PB, whole BM and CD34-positive cells, which clustered together.
Interestingly, these three controls showed hypermethylation of genes
like RUNX3 whereas in lymphoid cells, RUNX3 was unmethylated.
Lymphoid cells derived from PB, like B-cells, T-cells and PBLs
clustered together. T-cells showed a homogeneous epigenetic pattern
with hypomethylation of genes expressed in T-cells like ITK,
CTLA4 or ZAP70. DNA methylation profiles of B-cells like CD19-
positive PB cells, GC B-cells and LBL cell lines were heterogeneous.
B-cell specific genes like BLK were hypomethylated in all three
control types, but a higher number of hypomethylated genes were
detected only in GC B-cells and/or LBL cell lines. Expectedly, as
PBLs mostly contain a mixture of B- and T-cells, their methylation
profile was in between that obtained for B- and T-cells.
According to these results, WPB, WBM and CD34-positive cells
were used as controls for myeloid neoplasms and CD3-positive T-
cells as controls for T-cell neoplasms. Considering the heteroge-
neous nature of the nine subtypes of B-cell neoplasms analyzed
herein, we decided to group CD19-positive cells, GCB cells and
LBL cell lines as controls. As PBLs contain a mixture of B and T
cells, they were not used as control samples either for B cell or for
T cell neoplasms.
Global DNA methylation profiles in different subtypes of
hematopoietic neoplasms
A hierarchical cluster analysis of methylation values of 1410
CpGs in 367 hematological malignancies and 30 control samples
(excluding PBL samples, which are composed of both B- and T-
cells) is shown in Figure 2. Lymphoid malignancies were generally
associated with higher levels of de novo DNA methylation than
myeloid malignancies, which were mostly unmethylated and
clustered together with normal control samples (Figure 2 and
Figure 3A). Interestingly, high levels of de novo DNA methylation
seemed to be prevalent especially in germinal center B-cell derived
lymphomas like DLBCL, INT, mBL and FL, and lymphoid
precursor cell derived tumors like B-lineage ALL (B-ALL) and T-
lineage ALL (T-ALL).
The hierarchical cluster analysis in Figure 2 indicates that
although some entities tend to cluster together (e.g. myeloid
tumors or T-PLL), DNA methylation is heterogeneous within HN
subtypes, especially in lymphoid tumors.
Separate cluster analyses of B-cell, T-cell and myeloid
neoplasms with their respective controls are shown in Figure S1,
Figure S2, and Figure S3.
DNA Methylation in Lymphomas
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Figure 1. Hierarchical cluster analysis of CpGs differentially methylated in distinct non-malignant hematopoietic cell types.
doi:10.1371/journal.pone.0006986.g001
DNA Methylation in Lymphomas
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Detection of genes acquiring de novo DNA methylation
in different subtypes of hematological neoplasms
To identify genes de novo methylated in hematological
neoplasms, differential methylation analysis (DMA) was performed
comparing each tumor entity with the appropriate control
samples. A summary of the results of the DMA is shown in
Figure 3A and Figure 4A. A total of 354 CpGs (belonging to 220
genes) were shown to be hypermethylated in at least one entity.
The heatmap on Figure 4C shows differentially methylated CpGs
arranged according to the frequency of appearance in one or more
HNs. The analyses shown in Figure 4 indicate that most of the
hypermethylated genes are present in one or few malignancies and
that a small number of genes are hypermethylated across HNs.
A list of de novo methylated genes in each tumor entity is shown
in Table S4.
B-cell neoplasms. The DMA analyses in B-cell tumors showed
that 326 CpGs (belonging to 202 genes) were statistically significantly
hypermethylated in at least one subtype (Figure 3A, Figure 4A). Fifty-
eight genes were shown to be de novo methylated in precursor B-ALLs.
In mature B-cell tumors, a highly heterogeneous picture of DNA
hypermethylation was obtained. Some entities like DLBCLs, INTs,
mBLs and FLs were characterized by a high number of de novo
methylated genes, which ranged from 87 in mBL to 251 in DLBCL.
Other mature B-cell tumors like MCL or MM displayed an
intermediate degree of de novo DNA methylation, showing 32 and
42 hypermethylated genes, respectively. Finally, B-CLLs and MALT
lymphomas showed low levels of de novo DNA methylation, with only
three genes being significantly methylated in each entity.
T-cell neoplasms. DMA comparing T-cell tumors versus T-
cell control samples showed that 164 CpGs (108 genes) were
hypermethylated in at least one T-cell neoplasm. The great
majority of these genes were associated with T-ALL, in which 156
CpGs belonging to 103 genes were hypermethylated (Figure 3A).
In contrast, the mature T-cell tumors studied displayed low levels
of de novo DNA methylation, being one gene hypermethylated in
PTCL, five in ALCL and six in T-PLL.
Myeloid neoplasms. A DMA in myeloid tumors showed
that these entities were globally characterized by low levels of de
novo DNA methylation (Figure 3A). In AML, a total of 11 CpGs
(belonging to 9 genes) were shown to be hypermethylated. In
MDS/MPS and CML, DMA did not detect any hypermethylated
gene using the applied criteria.
Commonly hypermethylated genes. Of the 767 genes
analyzed only six genes (0.8%) were commonly hypermethylated
in HNs (Figure 4A), namely DBC1, DIO3, FZD9, HS3ST2, MOS
and MYOD1. In contrast, the vast majority of the genes being
Figure 2. Hierarchical cluster analysis of DNA methylation data obtained from 367 HNs and 30 control samples. The upper bar below
the dendrogram points to the specific HN subtype whereas the lower bar points to a classification of HNs according to the cell of origin (i.e. B-cell, T-
cell, or myeloid cell). DLBCL: diffuse large B-cell lymphoma, INT: intermediate lymphoma, mBL: molecular Burkitt lymphoma, FL: follicular lymphoma,
MCL: mantle cell lymphoma, MM: multiple myeloma, B-CLL: B-cell chronic lymphocytic leukemia, MALT: mucosa-associated lymphoid tissue
lymphoma, B-ALL: precursor B-cell acute lymphoblastic leukemia, T-ALL: precursor T-cell acute lymphoblastic leukemia, ALCL: anaplastic large cell
lymphoma, PTCL: peripheral T-cell lymphoma, T-PLL: T-cell prolymphocytic leukemia, AML: acute myeloid leukemia, MDS: myelodysplastic syndrome,
CML: chronic myelogenous leukemia, PB: peripheral blood, BM: bone marrow, CD34: CD34-positive cells.
doi:10.1371/journal.pone.0006986.g002
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hypermethylated in T-cell lymphomas were also found becoming
hypermethylated in B-cell lymphomas (92 genes corresponding to
85% of all hypermethylated genes).
Loss of gene-specific DNA methylation in hematological
malignancies
DMA to detect genes suffering de novo loss of DNA methylation
was performed comparing B-cell, T-cell and myeloid tumors with
their respective control samples. These analyses indicate that gene-
specific DNA hypomethylation, although less frequent than DNA
hypermethylation, is also a common finding in hematological
tumors (Figure 3A), at least for the 767 genes under analysis. The
highest number of hypomethylated genes was found in B-cell
neoplasms (96 genes), followed by T-cell (47 genes) and myeloid
neoplasms (4 genes). However, none of these genes analyzed
became hypomethylated in all entities (Figure 4B). A list of
hypomethylated genes in each tumor entity is shown in Table S5.
Correlation between de novo loss and gain of gene-
specific DNA methylation in hematological malignancies
Figure 3 and Figure 4 suggest that some tumors with a large
number of hypermethylated genes were accompanied by increased
levels of hypomethylated genes. To investigate whether gene-
specific DNA hypermethylation was associated with DNA
hypomethylation, we calculated Pearson correlation coefficients
and plotted the average methylation values per case for all hyper-
and hypomethylated genes in HNs with at least 10 hypermethy-
lated genes. The results indicate that DNA hypermethylation
significantly correlates with DNA hypomethylation in most mature
B-cell tumors, i.e. cases with higher levels of hypermethylation also
show higher levels of hypomethylation. In contrast, B- and T-ALL,
although they are heavily methylated, they do not show a
concurrent de novo loss of DNA methylation (Figure 5).
Association between PRC2 targets in stem cells and
genes differentially methylated in hematological
malignancies
We investigated whether genes showing significant differential
methylation in HNs were among those repressed by the PRC2 in
embryonic stem cells [27]. As shown in Figure 3B, between 32%
and 59% of the genes suffering de novo methylation in HNs are
PRC2 targets in embryonic stem cells. As compared with the 21%
of PRC2 targets in all the genes studied with the array, this
enrichment was statistically significant in all HNs studied but MM
and AML (Table S6). In contrast, only 5 to 13% of the
hypomethylated genes were PRC2 targets in embryonic stem cells.
These findings indicate that, regardless of the cellular nature of the
HN entity, de novo DNA methylation of a large proportion of genes
seems to be mediated by members of the polycomb complex.
The promoter regions of genes losing or acquiring DNA
methylation show different CpG content
To investigate whether the promoter regions of the genes
differentially methylated in different hematological tumors showed
a specific CpG composition, we classified them into high (HCP),
intermediate (ICP) and low (LCP) CpG content using a recent
classification system [28]. In line with previous reports [16], our
analysis demonstrated that genes acquiring de novo methylation in
tumors are mostly characterized by promoters with high CpG
content (Figure 3C). In contrast, the proportion of CpGs in gene
promoters showing de novo loss of DNA methylation in
hematological tumors is usually low (Figure 3C).
Figure 3. Bar plot of the differentHNs under study showing for each entity. (A) The number of genes/CpGs hypermethylated or hypomethylated,
(B) the percentage of differentially methylated genes marked by the PRC2 in ESCs, and (C) the percentage of differentially methylated genes showing
distinct promoter subtypes according to their CpG content. LCP: low CpG content, ICP: intermediate CpG content, HCP: high CpG content.
doi:10.1371/journal.pone.0006986.g003
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Loss of gene-specific DNA methylation is more frequent
than hypermethylation in T-PLL and correlates with
increased gene expression
DNA hypermethylation is clearly more frequent than
hypomethylation in HNs (Figure 3A). However T-PLL repre-
sents a striking exception to that observation. The four CD3+
tumor cells of the T-PLLs studied show a homogeneous DNA
methylation profile characterized by multiple genes suffering de
novo loss of DNA methylation (n = 44) and few hypermethy-
lated genes (n = 6). Comparing microarray-based gene expres-
sion of hypomethylated genes in the CD3+ T-PLLs cells to
CD3+ T-cell controls, we detected a total of 38 tags showing at
least a 0.5 fold (in log2 scale) increase in gene expression in T-
PLL vs T-cell controls. These include PDGFB, MMP3, DDR1,
IL1RN, IL10, CSF3R or SEPT9, which predominantly contained
promoters with low CpG content (LCP) (Figure 6B). In contrast,
only 5 tags showed log2 fold change values below 20.5. The
remaining 23 tags showed fold changes between 20.5 and 0.5.
These results indicate that gene promoter hypomethylation is
frequently associated with increased gene expression in T-PLL
(Figure 6).
Discussion
The main goal of this study was to provide a general overview of
DNA methylation changes associated with the most common
subtypes of HNs. These HNs were derived from different cell
lineages of the hematological system, i.e. B-cells, T-cells and myeloid
cells at different stages of differentiation. As DNA methylation profiles
are tissue and cell type-specific [29], we initially analyzed methylation
profiles of various cell types and tissues of the hematopoietic system to
identify appropriate control samples for the different HNs under
study. In this way, we eliminated cell lineage-specific biases and were
able to detect tumor-specific DNA methylation changes.
Statistical analyses of the microarray data identified the presence
of DNA methylation changes associated with the 16 different
subtypes of HNs under study. Our data clearly indicate that DNA
hypermethylation patterns are not homogenous across different
HNs. At the global level, we could observe that lymphoid neoplasms
generally showed a higher number of de novo methylated genes
than myeloid neoplasms. Interestingly, most myeloid neoplasms
only showed low levels of aberrant DNA methylation and clustered
together with the normal control samples (Figure 2).
Figure 4. Venn diagrams showing the overlap of genes. (A) Hypermethylated or (B) hypomethylated in B-cell, T-cell and myeloid neoplasms.
Only six genes were significantly hypermethylated in neoplasms of B-cell, T-cell and myeloid origin. We did not detect any gene hypomethylated in
tumors of all three cellular origins. (C) Heatmap containing all the CpGs hypermethylated (above) or hypomethylated (below) in at least one HN
subtype. CpGs are arranged in decreasing order of hypermethylation frequency. The presence of hypermethylated or hypomethylated CpGs in a
given HN subtype is shown on the right of the heatmap (black: differentially methylated).
doi:10.1371/journal.pone.0006986.g004
DNA Methylation in Lymphomas
PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e6986
Using the defined statistical criteria (see methods section), we
detected DNA methylation changes characteristic for the HN
entities under study (Table S4 and Table S5). Overall, we have
identified 343 genes differentially methylated in at least one entity.
Of these genes 220 become hypermethylated while 123 become
hypomethylated. In line with previous reports in solid tumors
[30,31,32,33] and mature aggressive B-cell lymphomas [16], a
high proportion of genes de novo methylated in various HN
subtypes were repressed by PRC2 in embryonic stem cells.
As well as genes predominantly methylated in certain HN
subtypes, we also identified six genes, i.e. DBC1, DIO3, FZD9,
HS3ST2, MOS and MYOD1, that were significantly hypermethy-
lated in B-cell, T-cell and myeloid malignancies. Hypermethylation
of DBC1, HS3ST2 and MYOD1 has been reported before not only
in HNs [12,18,34,35,36,37] but also in solid tumors [38,39,40].
Therefore, silencing of these genes by hypermethylation seems to be
a frequent pathomechanism associated with most human cancers.
FZD9 (Frizzled homolog 9) is a receptor for WNT2 in the WNT
pathway, from which several members have been shown to be
epigenetically deregulated in HNs [41]. De novo methylation of
FZD9 has been recently reported to be a frequent event in AML
samples and an independent predictor of prognosis for patients with
MDS/AML [12]. In our series, FZD9 was shown to be significatively
methylated in AML, but not in MDS or CML (Table S4).
The MOS (V-mos Moloney murine sarcoma viral oncogene
homolog) gene has been previously identified as hypermethylated in
ALL but not in AML [17]. In our series, although MOS is more
frequently hypermethylated in ALL (mean beta value = 0.64) than
in AML (mean beta value = 0.48), it also shows significant
hypermethylation in AML. Another recent study shows that MOS
is hypermethylated in AMLs with silenced CEPBA [18], suggesting
that MOS is hypermethylated only in some AML subtypes.
DIO3 (Deiodinase, iodothyronine, type III) is located in the
imprinted region in chromosome band 14q32 and plays an essential
role for regulation of thyroid hormone inactivation during embryo-
logical development. Recent data have shown that this gene is not
expressed or expressed at low levels in hematological cells [42]. In spite
of this lack of expression, our data indicate that the hypermethylated
DIO3 CpG site in HNs is unmethylated in controls. Recently, DIO3
was found to be methylated in AMLs with CEBPA silencing [18].
Remarkably, we observed that precursor B- and T-cell
neoplasms, i.e. precursor B-ALL and T-ALL, as well as mature
B-cell neoplasms with features of germinal center like DLBCL,
INT, mBL and FL are characterized by a large number of
hypermethylated genes. In contrast, other lymphoid malignancies
like MCL, MM, B-CLL, MALT, ALCL and T-PLL show
intermediate to low DNA hypermethylation. These data suggest
that lymphoid tumors arising from precursor cells and germinal
center cells tend to acquire higher levels of de novo DNA
methylation. Specific physiological rearrangements of immuno-
globulin (IG) and T-cell receptor (TCR) genes differentiate these
two stages of lymphocyte development from other maturation
stages. VDJ rearrangements of IGH and TCR genes take place in
precursor B-cell and T cells in the bone marrow, respectively,
whereas class switch recombination of the IGH locus takes place in
germinal centers of secondary lymphoid organs like lymph nodes.
A possible link between physiological genetic rearrangements,
lymphoid developmental stages and DNA methylation is derived
from reports indicating that the polycomb protein EZH2 is
involved in B-cell development and VDJ recombination [43], and
that EZH2 is able to lead to DNA methylation through
recruitment of DNA methyltransferases (DNMTs) [44]. Further-
more, immunohistochemical studies have revealed that EZH2
levels are higher in precursor T-cells than in resting mature T-cells
[45], and that in the germinal center, proliferating centroblasts
express EZH2 whereas non-proliferating centrocytes and naı¨ve B
cells do not [46]. In this scenario, we hypothesize that the features
of the cell that initiates development of lymphoid neoplasms or the
Figure 5. Scatter plots of mean methylation values of hypermethylated genes (Y axis) and hypomethylated genes (X axis) in HNs
with more than 10 hypermethylated genes. This figure shows that there is a significant correlation between the level of DNA hypermethylation
(increasing beta values) and DNA hypomethylation (decreasing beta values) in cases diagnosed with DLBCL, INT, FL, MCL and MM. In contrast, such
phenomenon is not observed in mBL and precursor lymphoid leukemias like B-ALL and T-ALL.
doi:10.1371/journal.pone.0006986.g005
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stage at which the tumor is frozen might shape the acquisition of
DNA methylation changes. We postulate that germinal center
lymphomas like DLBCL, INT, mBL and FL and precursor
lymphoid neoplasms like pre B-ALL and T-ALL are initiated or
frozen in developmental stages with proliferating cells and high
EZH2 expression. Thus, eventual recruitment of DNMTs by
EZH2 can then lead to a high level of aberrant DNA methylation
in precursor and germinal center lymphoid neoplasms. The fact
that neoplasms derived from myeloid cells, that do not suffer such
physiological rearrangements, display low levels of aberrant DNA
hypermethylation might support our hypothesis.
Another interesting finding derived from our data is that DNA
hypermethylation is accompanied in mature B-cell lymphomas
(with the exception of mBL) by gene-specific DNA hypomethyla-
tion (Figure 3, Figure 4, and Figure 5). In fact, cases with a large
number of hypermethylated genes concurrently show large
numbers of hypomethylated genes. In contrast, this effect is not
observed in precursor lymphoid neoplasms like T-ALL or B-ALL
(Figure 5). It has been widely reported in the literature that tumors
show global hypomethylation of DNA repeats and local hyper-
methylation of gene promoters [4]. However, gene hypomethyla-
tion has received less attention [47,48], although our data indicate
that it is also a frequent phenomenon in cancer, at least in HNs.
To our knowledge, correlation between levels of gene hyper- and
hypomethylation has not been reported before.
In general, DNA hypermethylation is more frequent than DNA
hypomethylation in HNs (Figure 3A). However, T-PLL, a rare
mature T-cell neoplasm, represents an exception to this general
rule. This neoplasm is characterized by a large number of
hypomethylated genes and few hypermethylation events. DNA
hypomethylation in T-PLL, and HNs in general, frequently targets
promoters with low CpG content (Figure 3C), whose methylation
has been reported to be independent from gene expression [28]. In
the T-PLLs described here, however, most hypomethylated genes
were associated with increased gene expression as compared to
normal T cells (Figure 6) [26]. Some of these genes have been
shown to be involved in tumorigenesis. For instance, interleukin 10
(IL10) acts as a negative regulator in numerous immunmodulatory
processes [49]. Furthermore, IL10 expression has been correlated
with tumor progression being of prognostic value in distinct
entities [50,51,52]. Additionally, we here could show that both the
DNA methylation and gene expression profile of another key
Figure 6.Most genes showing hypomethylation of promoter regions in T-PLL are associatedwith increased gene expression. (A) Genes
hypomethylated in T-PLL as compared with CD3+ normal T cells. Genes are arranged alphabetically. (B) Gene expression of hypomethylated genes in T-
PLL cases as compared to CD3+ normal T cells. Genes are arranged according to their differential expression in T-PLL vs. normal controls (most
upregulated genes on the top). Genes showing at least a 0.5 fold increase (in log2 scale), no expression changes or a 0.5 fold decrease are marked with
orange, grey or green lines, respectively, on the right of the heatmap. The CpG content of the promoter sequences of the genes presented is depicted as
color code in a separate column (low CpG content (LCP) = blue, intermediate CpG content (ICP) = yellow, high CpG content (HCP) = red, white =data not
available). Two of the T-PLL cases (case 1 and case 3) have been studied both by DNA methylation and gene expression profiling. The normal CD3+ T
cells used for DNA methylation and gene expression profiling were different. * Gene expression data have been published before by Du¨rig et al. [26]
doi:10.1371/journal.pone.0006986.g006
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player of the interleukin signaling pathway, interleukin 1 receptor
antagonist (IL1RN), is altered in T-PLL. IL1RN has also been
shown to be involved in tumorigenesis in numerous tumor entities
[53,54,55,56].
DDR1 belongs to the family of tyrosine kinases with high impact
on cell transformation in distinct solid tumors [57,58,59]. Since
DDR1 inhibition significantly increases chemosensitivity, this protein
has been suggested to be a promising therapeutic target [60].
The platelet-derived growth factor (PDGFB) which becomes
also hypomethylated and differentially expressed in T-PLL is
involved in mitogenesis of mesenchymal cells and a known
oncogene [61,62,63].
Our findings not only provide new insights into the biology of HNs
but have potential therapeutic implications. DNA methylation
inhibitors like Decitabine and 5-Azacitidine are currently used in
clinical studies to treat patients with MDS and AML [64]. For
instance, results from a phase III study have indicated that treatment
of patients with higher risk MDS with 5-azacitidine results in
significant improvement in overall survival [65]. However, consid-
ering that MDS and AML are among those HNs with less number of
genes suffering de novo DNA methylation, we wonder whether part
of the therapeutic effect of DNMT inhibitors is not due to
demethylation of hypermethylated genes but rather a different
mechanism, e.g. a cytotoxic effect. In any case, if DNMT inhibitors
do base their therapeutic effect on demethylation of hypermethylated
genes, then HNs with higher levels of DNA hypermethylation, like
germinal center B-cell lymphomas and precursor lymphoid neo-
plasms, might theoretically be better targets for such drugs. DNA
methylation profiling could be then a useful approach to monitor the
association between epigenetic response and clinical response and to
stratify patients for treatment with demethylating agents.
Supporting Information
Figure S1 Hierarchical cluster analysis of DNA methylation
data obtained from B-cell neoplasms. Hierarchical cluster analysis
of DNA methylation data obtained from 203 B-cell neoplasms and
13 control samples. The bar below the dendrogram points to the
specific subtype. DLBCL: diffuse large B-cell lymphoma, INT:
intermediate lymphoma, mBL: molecular Burkitt lymphoma, FL:
follicular lymphoma, MCL: mantle cell lymphoma, MM: multiple
myeloma, B-CLL: B-cell chronic lymphocytic leukemia, MALT:
mucosa-associated lymphoid tissue lymphoma, B-ALL: precursor
B-cell acute lymphoblastic leukemia, LBL: lymphoblastoid cell
line, GCB: germinal center B-cells, PB-B: peripheral blood B-cells.
Found at: doi:10.1371/journal.pone.0006986.s001 (2.76 MB TIF)
Figure S2 Hierarchical cluster analysis of DNA methylation data
obtained from T-cell neoplasms. Hierarchical cluster analysis of
DNA methylation data obtained from 30 T-cell neoplasms and 5
control samples. The bar below the dendrogram points to the
specific subtype. T-ALL: precursor T-cell acute lymphoblastic
leukemia, ALCL: anaplastic large cell lymphoma, PTCL: periph-
eral T-cell lymphoma, T-PLL: T-cell prolymphocytic leukemia.
Found at: doi:10.1371/journal.pone.0006986.s002 (0.94 MB TIF)
Figure S3 Hierarchical cluster analysis of DNA methylation
data obtained from myeloid neoplasms. Hierarchical cluster
analysis of DNA methylation data obtained from 134 myeloid
neoplasms and 12 control samples. The bar below the dendrogram
points to the specific subtype. AML: acute myeloid leukemia,
MDS: myelodysplastic syndrome, CML: chronic myelogenous
leukemia, PB: peripheral blood, BM: bone marrow, CD34: CD34-
positive cells.
Found at: doi:10.1371/journal.pone.0006986.s003 (1.52 MB TIF)
Table S1 Raw data: methylation values.
Found at: doi:10.1371/journal.pone.0006986.s004 (5.96 MB
TXT)
Table S2 Raw data: Cy3-intensity.
Found at: doi:10.1371/journal.pone.0006986.s005 (5.13 MB
TXT)
Table S3 Raw data: Cy5-intensity.
Found at: doi:10.1371/journal.pone.0006986.s006 (5.13 MB
TXT)
Table S4 Hypermethylated genes per entity. This table
summarizes genes becoming hypermethylated in hematological
neoplasms.
Found at: doi:10.1371/journal.pone.0006986.s007 (0.06 MB
XLS)
Table S5 Hypomethylated genes per entity. This table summa-
rizes genes becoming hypomethylated in hematological neoplasms.
Found at: doi:10.1371/journal.pone.0006986.s008 (0.04 MB
XLS)
Table S6 Percentage of hypermethylated genes targeted by the
PRC2 in ESCs. This table presents the percentage of hyper-
methylated genes which become targeted by the polycomb
repressor complex 2 (PRC2) in embryonal stem cells (ESCs) in
distinct lymphoma entities.
Found at: doi:10.1371/journal.pone.0006986.s009 (0.03 MB
DOC)
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